Scholar Rock provides 2026 priorities; ~$365M cash; apitegromab BLA resubmission expected in 2026

Scholar Rock Holding Corp

Preliminary cash of ~$365M as of Dec 31, 2025; expected runway into 2027.
Apitegromab BLA resubmission for SMA anticipated in 2026; U.S. launch expected after FDA approval.
IND cleared for FSHD; Phase 2 FORGE trial initiation and dosing expected mid-2026.
Subcutaneous apitegromab Phase 1 completed; SRK-439 Phase 1 topline data expected H2 2026.
EMA MAA decision for apitegromab expected mid-2026; second U.S. fill-finish facility capacity reserved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.